skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Etoposide Prodrug CAP7.1 (Code C114977)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Etoposide Prodrug CAP7.1

Definition: A prodrug of etoposide, a semisynthetic derivative of podophyllotoxin extracted from the mandrake root Podophyllum peltatum, with potential antineoplastic activity. Upon intravenous administration of the etoposide prodrug CAP7.1, etoposide is released after enzymatic cleavage of CAP7.1 by specific carboxylesterases (CE) 1 and 2, which are upregulated in certain tumor cell types. Etoposide acts primarily in the G2 and S phases of the cell cycle. This drug binds to and inhibits topoisomerase II, an enzyme elevated in tumor cells. This results in the accumulation of double-strand DNA breaks, the inhibition of DNA replication and transcription and the induction of apoptotic cell death. The tumor-specific activation of etoposide increases its efficacy while lowering its systemic toxicity.

Label: Etoposide Prodrug CAP7.1

NCI Thesaurus Code: C114977 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL472574  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Etoposide Prodrug CAP7.1

External Source Codes: 
PDQ Closed Trial Search ID 759515
PDQ Open Trial Search ID 759515 (check for NCI PDQ open clinical trial info)

Other Properties:
     Name Value (qualifiers indented underneath)
code C114977
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom